Stockreport

Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer’s Disease

Voyager Therapeutics, Inc.  (VYGR) 
Last voyager therapeutics, inc. earnings: 3/3 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.voyagertherapeutics.com
PDF - Topline SAD data from healthy volunteers demonstrate safety, tolerability, and dose-proportional pharmacokinetics, supporting potentially best-in-class profile - - MA [Read more]